One Center • One Focus • One Team

Dr. Nimmi Kapoor

HomeDr. Nimmi Kapoor

About Dr. Nimmi Kapoor

Dr. Nimmi Kapoor is a surgical oncologist specializing in breast and thyroid conditions. She practices at Breastlink Encino.

When is Double Mastectomy Appropriate?

Most women have heard of mastectomy, which is commonly performed to treat or reduce risk for breast cancer. In the age of improved cancer treatment, improved screening tools, and emphasis on long-term survival and benefits, it is important to question exactly when and for who a double mastectomy is beneficial.

Risk-Reducing Prophylactic Mastectomy

Prophylactic mastectomy is the most commonly performed preventive surgery in women at very high risk for breast cancer. Prophylactic mastectomy involves the surgical removal of virtually all breast tissue. Some high-risk women with no previous breast cancer diagnoses may consider this option. Some women previously diagnosed with breast cancer may also consider prophylactic mastectomy in their unaffected breast to […]

Takeaways from the 2016 ASCO Cancer Survivorship Symposium

On January 15, the American Society of Clinical Oncologists hosted the inaugural Survivorship Symposium in San Francisco. More than 800 doctors from numerous disciplines, researchers, patients and patient advocates gathered for the event focused on advancing cancer survivorship care issues. I recently wrote a joint article for Breast Cancer Social Media Community about the 2016 ASCO Survivorship Symposium with Stacey Tinianov, a breast cancer survivor and patient advocate.

Personalized Care for Cancer Survivors

One theme at the 2016 ASCO Survivorship Symposium was “One Size Fits No One.” There are more than 14 million cancer survivors in the United States and their needs vary. Several presentations revolved around the need for a […]

Developments in Multi-Gene Panel Tests for Breast Cancer

Numerous genetic mutations are linked to increased risk for breast cancer. Genetic testing can identify these mutations and guide patient management decisions. Over the past decade, multi-gene panel tests have gained traction in clinical settings. These evaluate up to 43 breast cancer-related genes, compared with limited BRCA 1 and BRCA2 (BRCA1/2) tests. In a recent review for World Journal of Surgical Procedures, I discussed whether multi-gene panel testing should replace limited BRCA1/2 testing.

Background to Genetic Testing

Since the mid-1990s, we have known about the link between BRCA1/2 and risk for breast cancer, which account for 30 to 50 percent of breast cancers. There are now well-established clinical guidelines for the […]

The Impact of Multi-Gene Panel Testing for Cancer Survivors

Multi-gene panel testing has recently emerged as a safe and effective way to identify genetic mutations known to increase risk for breast cancer. Compared with earlier genetic tests, which required initial testing for BRCA1 and BRCA2 followed by subsequent testing for other cancer-related genes, multi-gene panel testing can evaluate up to 43 genes. At Breastlink, we recently conducted a study to see how multi-gene panel testing affected treatment and screening decisions in cancer survivors who had previously tested negative for BRCA1/2.

IMG_3923 edited

How Does Management Change for Cancer Survivors with Positive Results?

For our study, we retrospectively collected data from 914 Breastlink patients who […]

Breastlink Research at the 2015 San Antonio Breast Cancer Symposium

Every year, the San Antonio Breast Cancer Symposium (SABCS) hosts one of the most important breast cancer conferences in the world. Experts across various specialties gather to share updates in cutting-edge breast cancer treatments and interventions. At the 2015 SABCS, Breastlink joined the discussion to share research we’ve been working on with patients in Orange County.

I had the opportunity to present a research poster and host a discussion on the results of a Breastlink study that I led: “Multi-gene panel testing and the cancers identified in patients at risk for hereditary breast cancer.” Dr. John Link presented a research poster based on another study we conducted: “The Breast Cancer Index […]

The 2015 ASCO Breast Cancer Symposium in Review

Every year, the American Society of Clinical Oncologists hosts a Breast Cancer Symposium to promote discussion about developments in breast cancer care and treatment. This event is an exceptional opportunity to learn about current trends and future directions that affect our patients and our daily practice. I was excited to attend the 2015 ASCO Breast Cancer Symposium and appreciate the thought-provoking dialogue that occurred.  In addition, I was also invited to present our own data on multi-gene panel testing.

Several topics of interest included the development of a new model for evaluating breast cancer risk in women with atypical hyperplasia, new data on recurrence in women with ductal carcinoma in situ […]

Personalized Care & Breast Cancer Screening: A Response to Revised ACS Guidelines

Middle Aged Woman Getting Mammogram

Breast cancer is a common and still lethal disease in the United States. More than 230,000 are likely to be diagnosed with breast cancer this year and it is expected to claim more than 40,000 lives.[1] Early detection of breast cancer saves lives and can minimize treatment.

Earlier this year, Breastlink responded to updated U.S. Preventive Services Task Force (USPSTF) recommendations to delay screening mammography until age 50 by emphatically detailing the potential harms of delaying a cancer diagnosis. These harms include increased toxicity of chemotherapy, more extensive surgery and a higher risk of lymphedema, as well […]

Surgery for All Thyroid Nodules? An Approach Based on Molecular Profiling

Many people — in fact, most people, — have thyroid nodules. Most nodules are benign or non-cancerous. Figuring out which nodules are cancerous can be challenging. Fortunately, there are molecular tests available that can help to sort out these challenges.

Years ago, my colleagues and I worked on research in this field and identified a molecular profile that can predict which thyroid nodules have malignant, or cancerous, potential. Now, commercial labs even make use of molecular profiling to help guide patients and physicians when deciding on surgery.

Background

A thyroid nodule is a growth of cells that form a mass in the thyroid gland. The thyroid gland, located in the front of the […]

By |July 13, 2015|Categories: Surgery|2 Comments

How Do Single-Gene & Multi-Gene Tests Compare?

The landscape of testing for hereditary cancer predisposition genes has been in rapid evolution. Recently developed tests can evaluate up to 43 genetic mutations associated with increased risk for a variety of cancers including breast cancer. Using data collected from our clinics, my Breastlink colleagues and I have analyzed how safe and effective these newer multi-gene tests are in comparison to previous methods of genetic testing.

Genetic Mutations breast cancer | gene tests

The Development of Multi-Gene Tests for Breast Cancer Risk

Two key events have helped change the face of genetic testing:

  • Technology became so advanced with next generation sequencing that it became as simple […]

Breast Biopsy Results Not Always Accurate

The results from a recent breast biopsy study reinforce the importance pathologists play in the management of breast diseases. Oncologists can have all the greatest tools at their disposal, but without an accurate diagnosis, these tools can be rendered useless.

A new study, published in The Journal of the American Medical Association (JAMA), provides further evidence towards this inclination. The March 2015 study suggests that pathologist frequently disagree on some high-risk breast lesions.

Breast Biopsy | Is it ADH or DCIS?

To diagnose a breast lesion, tissue is sampled from a patient’s breast using a biopsy needle and sent to a laboratory for testing. A pathologist, a physician […]

Load More Posts